David A. Siegel Viridian Therapeutics, Inc.\De Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Two Sigma Advisers, LP holds 93,800 shares of VRDN stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

93,800

Previous 193,300 51.47%

Holding current value

$2.09 Million

Previous $2.61 Million 49.67%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$11.02 - $16.09 $1.1 Million - $1.6 Million	-99,500 Reduced 51.47%	93,800 $1.31 Million
Q1 2025 May 15, 2025	SELL	$13.48 - $20.91 $1.92 Million - $2.97 Million	-142,269 Reduced 42.4%	193,300 $2.61 Million
Q4 2024 Feb 14, 2025	SELL	$17.85 - $25.71 $1.95 Million - $2.81 Million	-109,231 Reduced 24.56%	335,569 $6.43 Million
Q3 2024 Nov 14, 2024	SELL	$12.16 - $23.33 $995,904 - $1.91 Million	-81,900 Reduced 15.55%	444,800 $10.1 Million
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.26 $2.58 Million - $3.84 Million	222,300 Added 73.03%	526,700 $6.85 Million
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $3.49 Million - $4.86 Million	204,100 Added 203.49%	304,400 $5.33 Million
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $889,599 - $1.8 Million	80,000 Added 394.09%	100,300 $2.18 Million
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $163,728 - $266,760	10,800 Added 113.68%	20,300 $311,000
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $214,415 - $281,865	9,500 New	9,500 $226,000

Others Institutions Holding VRDN

# of Institutions

184

Shares Held

83M

Call Options Held

78.9K

Put Options Held

417K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $890M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account